Coronavirus vaccine

A composition comprising an RNA molecule having a nucleotide sequence that is at least 99% identical to that set forth in SEQ ID NO:

• 98, wherein:
• the RNA molecule comprises N1-methyl-pseudouridine in place of each uridine;
• the RNA molecule comprises a 5′ cap that comprises m27,3′-OGppp(m12′-O)ApG;
• and
• the RNA molecule is encapsulated in a lipid nanoparticle (LNP).

A composition comprising at least one unit dose of a population of lipid nanoparticles (LNPs), wherein

• each LNP in the population encapsulates at least one RNA molecule, wherein the at least one RNA molecule comprises:
• (a) a nucleotide sequence that is at least 95% identical to SEQ ID NO:
• 98 and which encodes a polypeptide, wherein the polypeptide:
• (i) has an amino acid sequence that is at least 95% identical to SEQ ID NO:
• 95;
• (ii) comprises a proline substitution at one or both positions corresponding to residues 986 and 987 of SEQ ID NO:
• 1;
• and
• (iii) comprises at least 10 of the following mutations as compared to SEQ ID NO:
• 1:
• T19I, Δ24-26, A27S, V83A, G142D, Δ144, H146Q, Q183E, V213E, G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P, G446S, N460K, S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, and Q954H;
• (b) N1-methyl-pseudouridine in place of each uridine;
• and
• (c) a 5′ cap that comprises m27,3′-OGppp(m12′-O)ApG.